Breaking Through Defenses, Delivering Hope.
Transforming Treatments with Cell Therapies
Ernexa Therapeutics is developing innovative stem cell therapies for the treatment of advanced cancer and autoimmune disease.
Engineered to Target. Designed to Impact Lives.
Partner with us
Core Technology
Our core technology focuses on engineering induced pluripotent stem cells (iPSCs) and transforming them into induced mesenchymal stem cells (iMSCs). iMSC is a more specialized type of stem cell that has a unique ability to migrate toward tumors or inflammation. Our allogeneic synthetic iMSCs provide a scalable, off-the-shelf treatment solution, without needing patient-specific cell harvesting.
...
See More
Our lead cell therapy product, ERNA-101, is designed to activate and regulate the immune system's response to recognize and attack cancer cells. With our best-in-class approach, iMSCs serve as a delivery vehicle to target tumors by leveraging their natural tumor-homing abilities, allowing them to slip through the tumor’s defenses and infiltrate tumor tissue. The iMSCs can then deliver potent anti-cancer agents directly to the tumor microenvironment, ultimately triggering a strong immune response against the cancer cells.
We are aiming to advance ERNA-101 into the clinic for the treatment of ovarian cancer as the first indication. Ovarian cancer currently lacks highly effective, widely applicable targeted therapies. Even when patients are treated successfully, there is a high recurrence rate.
ERNA-101 offers new hope for the countless women fighting ovarian cancer.
Partner with us
Targeting Inflammation, Advancing Treatment for Autoimmune Disease
ERNA-102 is our other cell therapy product designed to target inflammation and treat autoimmune disease. By calming overactive immune cells and promoting tissue repair, ERNA-102 aims to help treat autoimmune disease more effectively. With its unique mechanism of action, ability to last longer in the body, and design to precisely target the site of inflammation, ERNA-102 represents a promising next-generation, tissue-targeted therapy.
Current treatments for autoimmune disease are limited in their efficacy. ERNA-102 has the potential to bring significant hope to the treatment of autoimmune disease.